Glympse Bio Closes on $46.7 Million Series B Financing to Support Biosensor Platform in Fibrotic Diseases

Jul 16, 2020 | Investor Watch, News

Glympse Bio Closes on $46.7 Million Series B Financing to Support Biosensor Platform in Fibrotic Diseases

Glympse Bio has announced the closing of an oversubscribed $46.7 million Series B financing. The financing round was led by Section 32 and includes new investors Temasek, DNS Capital, New Leaf Venture Partners, Waterman Ventures, and Catalio Capital Management, as well as existing investors, including LS Polaris Innovation Fund, ARCH Venture Partners, CRV, GreatPoint Ventures, Gilead Sciences, and others also participated. The proceeds from the financing will support continued development of Glympse’s novel biosensor platform in fibrotic diseases such as Non-Alcoholic Steatohepatitis (NASH), oncology, and infectious diseases.

“The confidence and commitment from our new and existing investors further reinforces Glympse’s vision to improve the way diseases are understood, treatments are developed, healthcare is delivered, and patients are restored to health,” said Caroline J. Loew, Ph.D., President and Chief Executive Officer of Glympse. “Glympse will advance into PMA-enabling studies in NASH and explore the potential of the platform across multiple other diseases, such as oncology and infectious diseases. The addition of our new board members and expansion of our clinical advisory board will help to guide Glympse as we enhance our understanding of diseases, improve disease detection, and predict treatment response.”

The funding will be primarily used to support continued development of Glympse’s novel biosensor platform in NASH, a disease that impacts 16 million people in the U.S. and 100 million worldwide. The bioengineered, tunable sensors will be used to determine clinical trial participants’ stage of disease at initial screening and to determine response to study treatment in PMAenabling NASH studies. The biosensors avoid the difficulties seen with needle liver biopsy by providing a safe, repeatable, noninvasive measure of disease activity directly at the liver, thereby potentially predicting the stage of NASH in a patient long before histopathology changes become visible and enabling serial monitoring of treatment progress. Glympse completed first-in-human studies with their NASH product earlier this year. In addition to the NASH pivotal studies, the Series B funding will support further development of the company’s oncology program and initiate development of the infectious disease program.

Commenting on the funding, Wendy Winckler, Ph.D., Chief Scientific Officer, stated, “We have engineered tunable and specific biosensors to better understand complex diseases such as fibrosis, cancer, infections, and inflammation. Using a novel noninvasive approach, we can measure real-time biological signals that translate into clinically actionable results. We are paving the way to improve the continuum of care for NASH and build a comprehensive understanding of the disease trajectory that doesn’t currently exist. In oncology, we can directly track tumor progression at the site of disease and measure its response to treatment across a broad range of immunotherapies, targeted therapies, and other standards-of-care. This funding enables us to continue the development of our current programs and expand the application of our platform into new therapeutic indications.”

Source: glympse bio

0 Comments